ROIV Stock Overview A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Roivant Sciences Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Roivant Sciences Historical stock prices Current Share Price US$11.69 52 Week High US$13.06 52 Week Low US$9.69 Beta 1.25 1 Month Change 4.75% 3 Month Change -1.93% 1 Year Change 17.37% 3 Year Change -1.35% 5 Year Change n/a Change since IPO 12.40%
Recent News & Updates
Roivant Sciences: A Biotech Growth Play With Major Ambitions Dec 04
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis Dec 03
President & COO notifies of intention to sell stock Nov 21
Consensus revenue estimates decrease by 36% Nov 19
New major risk - Earnings quality Nov 14
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Nov 13 See more updates
Roivant Sciences: A Biotech Growth Play With Major Ambitions Dec 04
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis Dec 03
President & COO notifies of intention to sell stock Nov 21
Consensus revenue estimates decrease by 36% Nov 19
New major risk - Earnings quality Nov 14
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Nov 13
Roivant Sciences Ltd. to Report Q2, 2025 Results on Nov 12, 2024 Oct 30
Organon & Co. (NYSE:OGN) completed the acquisition of Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others. Oct 28
President & COO notifies of intention to sell stock Oct 23
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility Oct 22
Independent Director notifies of intention to sell stock Oct 03
CEO & Director recently sold US$5.1m worth of stock Sep 26
CEO & Director notifies of intention to sell stock Sep 25 Organon & Co. (NYSE:OGN) agreed to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others for approximately $1.2 billion. Sep 18
Statutory Earnings May Not Be The Best Way To Understand Roivant Sciences' (NASDAQ:ROIV) True Position Aug 22
Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses Aug 22
Consensus revenue estimates increase by 18% Aug 16
New major risk - Earnings quality Aug 11
First quarter 2025 earnings: EPS and revenues exceed analyst expectations Aug 09
Roivant Sciences Ltd., Annual General Meeting, Sep 10, 2024 Jul 29
Roivant Sciences Ltd. to Report Q1, 2025 Results on Aug 08, 2024 Jul 26
Full year 2024 earnings: EPS in line with expectations, revenues disappoint Jun 04
Roivant Sciences: Executing On Huge Buyback Program With More To Come Jun 02
Consensus revenue estimates decrease by 17%, EPS upgraded Jun 02
Now 20% undervalued Apr 08
President exercised options and sold US$3.9m worth of stock Apr 04 Roivant Sciences Ltd. (NasdaqGS:ROIV) announces an Equity Buyback for $1,500 million worth of its shares.
Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success Mar 18
We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability Feb 21
Consensus EPS estimates increase by 7,400% Feb 20
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Feb 14
President & COO notifies of intention to sell stock Feb 12
Roivant Sciences Ltd. to Report Q3, 2024 Results on Feb 13, 2024 Jan 31
Consensus EPS estimates increase from loss to US$0.07 profit Jan 25
Forecast to breakeven in 2024 Jan 25
Insider recently sold US$33m worth of stock Jan 04
High number of new directors Dec 01
Roivant Sciences Ltd. and Priovant Therapeutics, Inc. Announces Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus Nov 29
Roivant Sciences Ltd. and Priovant Therapeutics, Inc. Announces Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus Nov 28
Consensus EPS estimates fall by 12% Nov 20
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 14
Roivant Appoints Mayukh Sukhatme to its Board of Directors Nov 11
Roivant Sciences Ltd. to Report Q2, 2024 Results on Nov 13, 2023 Oct 31
President & COO notifies of intention to sell stock Sep 29
President & COO notifies of intention to sell stock Sep 07
Consensus revenue estimates fall by 11% Aug 21
President & COO notifies of intention to sell stock Aug 17
First quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 14
Roivant Sciences Ltd. Announces the Resignation of Hiroshi Nomura from Board of Directors, Effective from August 31, 2023 Aug 05
Roivant Sciences Ltd. to Report Q1, 2024 Results on Aug 14, 2023 Aug 04
Roivant Sciences Ltd., Annual General Meeting, Sep 12, 2023 Aug 01
President & COO notifies of intention to sell stock Jul 23
Roivant Sciences Reportedly Near Deal to Sell Stomach Drug to Roche for over $7 Billion Jul 16
Consensus estimates of losses per share improve by 14% Jul 05
Full year 2023 earnings: EPS and revenues exceed analyst expectations Jun 28
Roivant Sciences Ltd. to Report Q4, 2023 Results on Jun 28, 2023 Jun 27
Roivant Sciences Announces Positive Results from the Chronic Period of the Tuscany-2 Phase 2B Study of RVT-3101 Jun 23
Price target increased by 8.6% to US$14.78 Jun 23
President & COO notifies of intention to sell stock Jun 12
CEO & Director notifies of intention to sell stock May 26
Chief Accounting Officer notifies of intention to sell stock Apr 30
Now 20% undervalued Apr 25
High number of new directors Apr 02
CEO & Director notifies of intention to sell stock Mar 26
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 14 Roivant Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $200 million. Feb 04
Roivant Sciences Ltd. to Report Q3, 2023 Results on Feb 13, 2023 Jan 31
CEO & Director notifies of intention to sell stock Jan 27
Price target increased to US$13.13 Jan 20
President & COO notifies of intention to sell stock Jan 08
Price target increased to US$12.88 Jan 05
Roivant Sciences Ltd. Announces Positive Results from the Induction Period of the Tuscany-2 Phase 2B Study of RVT-3101 Jan 05
Price target increased to US$12.25 Dec 27
CEO & Director notifies of intention to sell stock Dec 26
President & COO notifies of intention to sell stock Dec 12
Roivant Sciences Ltd. Announces Resignation of Andrew Lo as Class II Director Nov 24
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 19
Consensus forecasts updated Nov 16
High number of new directors Nov 16 Roivant Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $150 million. Nov 10
Roivant Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $150 million. Nov 09
CEO & Director notifies of intention to sell stock Oct 27
Roivant Sciences Ltd. to Report Q2, 2023 Results on Nov 14, 2022 Oct 19
Consensus forecasts updated Sep 29 Shareholder Returns ROIV US Biotechs US Market 7D -3.5% -6.5% -4.0% 1Y 17.4% 1.3% 24.0%
See full shareholder returns
Return vs Market: ROIV underperformed the US Market which returned 26.1% over the past year.
Price Volatility Is ROIV's price volatile compared to industry and market? ROIV volatility ROIV Average Weekly Movement 3.8% Biotechs Industry Average Movement 10.7% Market Average Movement 6.4% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.2%
Stable Share Price: ROIV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ROIV's weekly volatility (4%) has been stable over the past year.
About the Company Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases.
Show more Roivant Sciences Ltd. Fundamentals Summary How do Roivant Sciences's earnings and revenue compare to its market cap? ROIV fundamental statistics Market cap US$8.84b Earnings (TTM ) US$4.60b Revenue (TTM ) US$129.13m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ROIV income statement (TTM ) Revenue US$129.13m Cost of Revenue US$552.21m Gross Profit -US$423.08m Other Expenses -US$5.02b Earnings US$4.60b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 6.31 Gross Margin -327.64% Net Profit Margin 3,558.52% Debt/Equity Ratio 0%
How did ROIV perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/18 03:02 End of Day Share Price 2024/12/18 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Roivant Sciences Ltd. is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ishan Majumdar Baptista Research Chi Meng Fong BofA Global Research Louise Chen Cantor Fitzgerald & Co.
Show 13 more analysts 
